Table S2 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Autor: Marc S. Ernstoff, Elizabeth A. Repasky, Hemn Mohammadpour, Igor Puzanov, Mark J. Bucsek, Joseph J. Drabick, Pauline Funchain, Suzanne Stack, Maria Levis, Carlos D. Cedeno, Paul K. Wallace, Joseph D. Tario, Cheryl Allen, Erik S. Knudsen, Agnieszka K. Witkiewicz, Wenyan Ji, Kristopher Attwood, Manu R. Pandey, Shipra Gandhi
Rok vydání: 2023
DOI: 10.1158/1078-0432.22479662
Popis: A. Absolute quantitative change in peripheral blood chemokines* from baseline to week 3 (week 3 minus baseline; change in mean value +/- standard deviation). B. Quantitative change in peripheral blood cellular fractions expressed as percentage of total CD45+ cells from baseline to 3 weeks (week 3 minus baseline).
Databáze: OpenAIRE